Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Dr. Voodoo who wrote (1297)	10/31/2000 5:32:03 PM
From: Ian@SI	Read Replies (1) \| Respond to of 1477

A rheumatologist acquaintance seems to like this morning's press release. His response to my query: The anti-TNF agents now available have to be given by injection whereas p38kinase inhibitors are oral. Furthermore IL-1 which damages cartilage is reduced and COX-2 is inhibited making need for nonsteroidal anti-inflammatories unnecessary. Also, it is not an antibody so that immune reactions to it compared to the TNF blockers should be less; cost should be less and dose adjustment should be easier.